$HIMS (-7,52%)
$LLY (-7,56%)
$NOVO B (-6,66%)
$NVO (-7,4%)

$NOVO B (-6,66%) introduces NovoCare ® Pharmacy, which lowers the cost of all doses of FDA-approved Wegovy ® (semaglutide) to $499 per month and offers convenient home delivery for cash-paying patients.
While 90% of patients taking Wegovy ® have a co-pay of $0 to $25 per month, this offer was developed to support patients who are self-pay and do not have insurance coverage.